Clinical trial data can drive discovery long after a study ends. Prilenia donated placebo-arm data from 2 HD clinical trials to CHDI, a valuable resource for researchers to better understand placebo effects, HD progression and future trial design.

⏱️10min read | Roche's decision to stop development of 2 HTT-lowering programmes is disappointing, but the story doesn't end there. Years of research answered some key questions, raised many new ones, and will inform the next generation of HD trials.

⏱️ 8 min read | July was a hard month for Huntington's disease research, with Roche ending two HD programs. But the month also brought promising new tools, a new player in somatic expansion, and important work on eating and self-awareness in HD.